IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Per Ogren

Confirmation No: 3515

Application No: 10/587,880

Art Unit: 2617

Filing Date: July 27, 2006

Examiner: Isaak R. Jama

SHARING META INFORMATION MEDIA FILE

June 24, 2009

Commissioner for Patents Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Sir:

Att	ached is	an Information Disclosure Statement listing of documents, together with a copy of any
isted foreig	ın paten	t document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S.
oatent appl	ication p	oublication is not provided herewith in accordance with 37 C.F.R. § 1.98(a)(2)(ii).
\boxtimes	In acco	rdance with 37 CFR 1.97(b), the information disclosure statement is being filed:
	□ (1)	within three months of the filing date of a national application other than a continued
		prosecution application under §1.53(d);
	☐ (2)	within three months of the date of entry of the national stage as set forth in §1.491 in an
		international application;
	(3)	before the mailing of a first Office Action on the merits; or
	(4)	before the mailing of a first Office Action after the filing of a request for continued
		examination under §1.114.
	In acco	ordance with 37 CFR 1.97(c), the information disclosure statement is being filed after the
period specified in 37 CFR 1.97(b) above, but before the mailing date of any of a final action under §1.113, a		
notice of al	lowance	under §1.311, or an action that otherwise closes prosecution in the application, and is
accompani	ed by <u>or</u>	ne of the following:
	□ (1)	The statement specified under 37 CFR 1.97(e), as follows:
		☐ Each item of information contained in the information disclosure statement was
	first cited in any communication from a foreign patent office in a counterpart foreign	
application not more than three months prior to the filing of the information disclosure		
statement; <u>or</u>		
		☐ No item of information contained in the information disclosure statement was
		ed in a communication from a foreign patent office in a counterpart foreign application,
		d, to the knowledge of the person signing the certification after making reasonable inquiry
		item of information contained in the information disclosure statement was known to any
	individual designated in §1.56(c) more than three months prior to the filing of the informatio	
	dis	closure statement; <u>or</u>
	(2)	The fee set forth in §1.17(p);

In re: Per Ogren Application No.: 10/587,880 Filing Date: July 27, 2006 Page 2 of 2 In accordance with 37 CFR 1.97(d), the information disclosure statement is being filed after the period specified in 37 CFR 1.97(c) above, but on or before payment of the issue fee, and is accompanied by **both** of the following: (1) The statement specified under **37 CFR 1.97(e)**, as follows: That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement; and \square (2) The fee set forth in §1.17(p); In accordance with 37 CFR 1.97(g), the information disclosure statement shall not be construed as a representation that a search has been made. In accordance with 37 CFR 1.97(h), the information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b). The Director is hereby authorized to charge the fee specified in 37 C.F.R. § 1.17(p), and any fee

The Director is hereby authorized to charge the fee specified in 37 C.F.R. § 1.17(p), and any fee deficiency or credit any overpayment, to Deposit Account No. 50-0220; or

No fee is believed due. However, the Director is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Laura M. Kelley

Registration No. 48,441 Attorney for Applicant(s)

Customer Number 54414

Myers Bigel Sibley & Sajovec, P.A. P.O. Box 37428, Raleigh, NC 27627 919-854-1400 919-854-1401 (Fax)

CERTIFICATION OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on June 24, 2009.

Joyce Paoli